The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The natural history of HER2-overexpressing (HER2+) metastatic breast cancer (MBC) treated with trastuzumab (T): Practical points to consider in developing treatment strategies.
Serena Di Cosimo
No relevant relationships to disclose
Danila Serpico
No relevant relationships to disclose
Anna Tessari
No relevant relationships to disclose
Luca Porcu
No relevant relationships to disclose
Leonardo Molino
No relevant relationships to disclose
Valter Torri
No relevant relationships to disclose
Filippo G. De Braud
Consultant or Advisory Role - Novartis; SERVIER
Research Funding - GlaxoSmithKline; Novartis; Pierre Fabre Medicament; Roche